Ibodutant
Ibodutant
Ibodutant (pronounced as /ɪˈbɒdjuːtænt/) is a selective antagonist for the neurokinin 1 receptor. It is currently under development for the treatment of irritable bowel syndrome (IBS) and other related gastrointestinal disorders.
Etymology
The term "Ibodutant" is a coined name for this specific drug. The prefix "Ibo-" is derived from its chemical structure, while "-dutant" is a common suffix for drugs that act as antagonists.
Pharmacology
Ibodutant works by blocking the neurokinin 1 (NK1) receptor, a protein that plays a key role in the transmission of pain signals in the body. By inhibiting this receptor, Ibodutant can potentially alleviate the symptoms of conditions like IBS, which are often characterized by chronic abdominal pain and discomfort.
Clinical Trials
Several clinical trials have been conducted to evaluate the safety and efficacy of Ibodutant in patients with IBS. The results of these trials have shown promising results, with patients reporting significant improvements in their symptoms. However, further research is needed to fully understand the long-term effects of this drug.
Related Terms
- Neurokinin 1 receptor
- Antagonist
- Irritable bowel syndrome
- Gastrointestinal disorders
- Clinical trials
External links
- Medical encyclopedia article on Ibodutant
- Wikipedia's article - Ibodutant
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski